Future research should focus on the following directions: optimizing the tumor-targeting ability of PROTACs to reduce off-target effects; combining the targeting of MYCN upstream and downstream pathways to overcome drug resistance; and exploring specific binding sites of the dynamic structure of the N-Myc and developing more selective inhibitors. Here, MYCN is linked to neoplasm.